Kazuhiko Nakagawa

发表

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

K. Matsumoto, K. Nishio, I. Okamoto, 2013, Oncogene.

A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.

H. Sasaki, T. Yamanaka, Y. Ichinose, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

K. Nishio, J. Tanizaki, K. Nakagawa, 2021, Clinical Cancer Research.

A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.

T. Yamanaka, Y. Ichinose, Y. Kogure, 2015, Annals of Oncology.

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

K. Nishio, I. Okamoto, J. Tanizaki, 2011, Oncogene.

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

H. Hayashi, Y. Togashi, Kazuhiko Nakagawa, 2014 .

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

H. Hayashi, Y. Togashi, Kazuhiko Nakagawa, 2014 .

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

H. Hayashi, Y. Togashi, Kazuhiko Nakagawa, 2014 .

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

H. Hayashi, Y. Togashi, Kazuhiko Nakagawa, 2014 .

Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer

K. Matsumoto, M. D. De Velasco, K. Nishio, 2011, British Journal of Cancer.

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

S. Tomida, J. Tanizaki, R. Hatae, 2024, The Journal of clinical investigation.

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toshio Shimizu, T. Seto, M. Takenoyama, 2016, Investigational New Drugs.

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

I. Okamoto, A. Tsuya, S. Sugawara, 2023, JAMA oncology.

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

T. Ohira, Y. Miyata, M. Takeda, 2024, JTO clinical and research reports.

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

J. Gainor, K. Ichikado, J. Sylvester, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study

Y. Ohde, H. Akamatsu, H. Tada, 2023, Molecular oncology.

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long‐term follow‐up results from KEYNOTE‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma

H. Uchi, H. Uhara, Y. Kiyohara, 2024, The Journal of dermatology.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

K. Nishio, T. Sudo, M. Tanioka, 2014, Breast Cancer Research and Treatment.